Convection-enhanced delivery for treatment of brain tumors

Expert Review of Anticancer Therapy

Volumn 7, Issue 12 SUPPL., 2007, Pages

  Ferguson, Sherise D ^a   Foster, Kimberly ^a   Yamini, Bakhtiar ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Chemotherapy; Convection enhanced delivery; Malignant glioma targeted toxins

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR I 125; CARBOPLATIN; CARMUSTINE; CINTREDEKIN BESUDOTOX; COTARA; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIN; FLUORESCENT DYE; GAMMA INTERFERON; GANCICLOVIR; GEMCITABINE; GLIADEL WAFER; HYBRID PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN FUSION PROTEIN; KSB 311; LIPOSOME; MONOCLONAL ANTIBODY; NBI 3001; NERVE GROWTH FACTOR I 125; PACLITAXEL; PARVOVIRUS VECTOR; RADIOISOTOPE; SUCROSE; TEMOZOLOMIDE; THYMIDINE KINASE; TOPOTECAN; TP 38; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONVECTION ENHANCED DELIVERY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG PENETRATION; DRUG RESPONSE; DRUG TOLERANCE; FEVER; GLIOBLASTOMA; GLIOMA; HUMAN; INFECTION; LIPOSOMAL DELIVERY; LYMPHOCYTOPENIA; MENINGITIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; REVIEW; SUICIDE GENE THERAPY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS AS TOPIC; CONVECTION; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; PROGNOSIS; RATS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38049120453     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.12.S79     Document Type: Review

References (46)

1. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17(8), 2572-2578 (1999).
2. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin. Oncol. 24(8), 1273-1280 (2006).
3. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34(6), 463-469 (1992).
4. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104(1), 29-45 (2004).
5. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40(3), 648-677 (1969).
6. Hall WA, Rustamzadeh E, Asher AL. Convection-enhanced delivery in clinical trials. Neurusurg. Focus 14(2), E2 (2003).
7. Mahar Doan KM, Humphreys JE, Webster LO et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol. Exp. Ther. 303(3), 1029-1037 (2002).
8. Neuwelt EA, Goldman DL, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J. Clin. Oncol. 9(9), 1580-1590 (1991).
9. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. cell. Mol. Neurobiol. 20(2), 217-230 (2000).
10. Walburg H, Walburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci. Lett. 307(2), 77-80 (2001).
11. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol, Exp. Ther. 195(1), 73-83 (1975).
12. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol. 127(1), 23-36 (1994).
13. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680(1-2), 196-206 (1995).
14. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91(6), 2076-2080 (1994).
15. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for Increasing drug delivery. Neuro-oncology 2(1), 45-59 (2000).
16. Guamieri M, Carson BS, Khan A, Penno M, Jailo GI. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J. Neurosci. Methods 144(2), 147-152 (2005).
17. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg. Focus 20 (4), E12 (2006).
18. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. 90(2), 315-320 (1999).
19. Sampson JH, Brady ML, Petry NA et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60(2 Suppl. 1), ONS89-ONS98; discussion ONS98-ONS99 (2007).
20. 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro-oncology 6(2), 104-112 (2004).
21. Saito R, Krauze MT, Noble CO et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology 8(3), 205-214 (2006).
22. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Biain Res. 1035(2), 139-153 (2005).
23. Chen MY, Hoffer A, Morrison PF et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. 103(2), 311-319 (2005).
24. Bruce JN, Falavigna A, Johnson JP et al. Intracerebral clysis in a rat glioma model. Neurosurgery 46(3), 683-691 (2000).
25. Heimberger AB, Archer GE, McLendon RE et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res. 6(10), 4148-4153 (2000).
26. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47(6), 1391-1398; discussion 1398-1399 (2000).
27. Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR, Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg. 99(5), 893-898 (2003).
28. Frewert S, Stockhammer F, Warschewske G et al. Intratumoral infusion of interteukin-1β and interferon-γ induces tumor invasion with macrophages, and lymphocytes in a rat glioma model. Neurosci. Lett. 364(3), 145-148 (2004).
29. Hadaczek P, Kohutnicka M, Krauze MT et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17(3), 291-302 (2006).
30. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65(1), 37-48 (2003).
31. Rainov NG, Soling A, Heidecke V. Novel therapies for malignant gliomas: a local affair? Neurusurg. Focus 20 (4), E9 (2006).
32. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. 72(6), 941-945 (1990).
33. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interieukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res. 61(22), 8058-8061 (2001).
34. Lidar Z, Mardor Y, Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J. Neurosurg. 100(3), 472-479 (2004).
35. Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium reyiew. J. Neurooncol. 83(1), 97-109 (2007).
36. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for Interleukin 13 and interleukin 4. J. Biol. Chem. 270(28), 16775-16780 (1995).
37. Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25(7), 837-844 (2007).
38. Weber F, Asher A, Bucholz R et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurient malignant giloma. J. Neurooncol. 64 (1-2), 125-137 (2003).
39. Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the Intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65(1), 27-35 (2003).
40. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3(12), 1362-1368 (1997).
41. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65(1), 3-13 (2003).
42. Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther 6(5), 539-545 (2006).
43. Patel SJ, Shapiro WR, Laske DW et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56(6), 1243-1252; discussion 1252-1253 (2005).
44. Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology 8(1), 60-66 (2006).
45. Voges J, Reszka R,Gossmann A et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54(4), 479-487 (2003).
46. Yamashita Y, Krauze MT, Kawaguchi T et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology 9(1), 20-28 (2007).